Dr. Falk is a clinical geneticist who serves as executive director of the CHOP Mitochondrial Medicine Frontier Program. She is the principal investigator of an active National Institutes of Health-, pharma-, and philanthropic-funded translational research laboratory that investigates the causes and global metabolic consequences of mitochondrial disease, as well as targeted therapies, in C. elegans, zebrafish, mouse, and human tissue models of genetic-based respiratory chain dysfunction. Dr. Falk is also PI on clinical trials to better characterize and test candidate therapies in patients living with mitochondrial disease.

The Mitochondrial Medicine Research Group under Dr. Falk's direction works to improve clinical care, diagnostic approaches, improved therapies, and robust genomic and bioinformatics resources for mitochondrial disease. In particular, the group organizes the global Mitochondrial Disease Sequence Data Resource (MSeqDR) Consortium to provide centralized curation and analytic capabilities for genomic analysis tools and integrated knowledge of genes, variants, and phenotypes relevant to mitochondrial disease.

BS, George Washington University (Biology), 1996

MD, George Washington University, 2000

Executive Director, Mitochondrial Medicine Frontier Program

Leader, Mitochondria Research Affinity Group

Attending Physician

Professor of Pediatrics

American Society of Human Genetics, 2002-

Society for Inherited Metabolic Disease, 2005-

Mitochondrial Medicine Society, 2006-

Society for Pediatric Research, 2007-

American College of Medical Genetics, 2010-

Mitochondria Research Society, 2011-

The Interurban Clinical Club, 2017-

American Society for Clinical Investigation, 2017-

Mitochondrial Medicine

Understanding Mitochondrial Disease Profile